Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection

Pediatric Pulmonology

Volumn 46, Issue 2, 2011, Pages 184-192

  Moskowitz, Samuel M ^a,b,c   Emerson, Julia C ^b,c   McNamara, Sharon ^c   Shell, Richard D ^d   Orenstein, David M ^e   Rosenbluth, Daniel ^f   Katz, Marcia F ^g   Ahrens, Richard ^h   Hornick, Douglas ^h   Joseph, Patricia M ⁱ   Gibson, Ronald L ^b,c   Aitken, Moira L ^b   Benton, Wade W ^c,j   Burns, Jane L ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^j Actelion Pharmaceuticals   (United States)

more..

Author keywords

antibiotic resistance; antibiotic susceptibility testing; broth microdilution testing; inhibitory quotient; intravenous antibiotics; lung function; Pseudomonas aeruginosa; sputum bacterial density

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; MACROLIDE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TOBRAMYCIN;

ADOLESCENCE; ADULT; ALGORITHM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BIOFILM; CLINICAL ARTICLE; COLONY FORMING UNIT; CYSTIC FIBROSIS; DIARRHEA; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SPUTUM SMEAR; THRUSH;

ADULT; ANTI-BACTERIAL AGENTS; BIOFILMS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY FLOW RATES; HUMANS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; PILOT PROJECTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPUTUM; THIENAMYCINS; YOUNG ADULT;

EID: 79251526157     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21350     Document Type: Article

References (30)

1. Cystic Fibrosis Foundation. CFF Patient Registry. Patient Registry Annual Data Report 2006, Bethesda, Maryland, 2008.
2. Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS,. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008; 43: 874-881.
3. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR,. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998; 27: 158-163.
4. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R,. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134: 413-421.
5. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL,. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45: 363-370.
6. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL,. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 1495-1502.
7. Gilligan PH,. Is there value in susceptibility testing of Pseudomonas aeruginosa causing chronic infection in patients with cystic fibrosis? Expert Rev Anti Infect Ther 2006; 4: 711-715.
8. Cystic Fibrosis Foundation. Consensus Conference: Microbiology and Infectious Disease in Cystic Fibrosis, Bethesda, Maryland: Cystic Fibrosis Foundation; 1994 May 17 and 18. pp 1-26.
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th edition M7-A7. Wayne, PA: CLSI; 2006.
10. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP,. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407: 762-764.
11. Moskowitz SM, Foster JM, Emerson J, Burns JL,. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42: 1915-1922.
12. Drenkard E, Ausubel FM,. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-743.
13. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA,. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426: 306-310.
14. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A,. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-1776.
15. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C,. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 2005; 43: 5085-5090.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement M100-S18, Vol. 28. Wayne, PA: CLSI; 2008.
17. Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL,. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 2005; 56: 879-886.
18. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
19. Foweraker JE, Laughton CR, Brown DF, Bilton D,. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 55: 921-927.
20. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL,. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
21. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ,. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009; 135: 1223-1232.
22. Blumer JL, Saiman L, Konstan MW, Melnick D,. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128: 2336-2346.
23. McLaughlin FJ, Matthews WJ, Jr., Strieder DJ, Sullivan B, Taneja A, Murphy P, Goldmann DA,. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983; 147: 559-567.
24. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC,. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141: 914-921.
25. Foweraker JE, Laughton CR, Brown DF, Bilton D,. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother 2009; 53: 4809-4815.
26. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Yozghatlian V, Bye P, Bell S, Chan F, Rose B, Jeanneret A, Stephenson A, Noseworthy M, Freitag A, Paterson N, Doucette S, Harbour C, Ruel M, MacDonald N,. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005; 366: 463-471.
27. Etherington C, Hall M, Conway S, Peckham D, Denton M,. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Antimicrob Chemother 2008; 61: 425-427.
28. Govan JR,. Multidrug-resistant pulmonary infection in cystic fibrosis-what does 'resistant' mean? J Med Microbiol 2006; 55: 1615-1617.
29. Keays T, Ferris W, Vandemheen KL, Chan F, Yeung SW, Mah TF, Ramotar K, Saginur R, Aaron SD,. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009; 8: 122-127.
30. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW,. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007; 42: 610-623.